|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
118,790,000 |
Market
Cap: |
42.71(M) |
Last
Volume: |
19,275,386 |
Avg
Vol: |
8,941,637 |
52
Week Range: |
$0.3595 - $0.3595 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M adjuvant.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
6,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
68,716 |
68,716 |
68,716 |
68,716 |
Total Sell Value |
$961,682 |
$961,682 |
$961,682 |
$961,682 |
Total People Sold |
2 |
2 |
2 |
2 |
Total Sell Transactions |
3 |
3 |
3 |
3 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Glenn Gregory M |
President, R&D |
|
2021-07-20 |
4 |
AS |
$200.61 |
$518,982 |
D/D |
(2,409) |
2,811 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-07-15 |
4 |
D |
$179.14 |
$403,602 |
D/D |
(2,253) |
5,220 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-07-15 |
4 |
D |
$179.14 |
$28,842 |
D/D |
(161) |
7,473 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-07-15 |
4 |
OE |
$5.95 |
$137,006 |
D/D |
10,477 |
7,634 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-07-15 |
4 |
AS |
$177.62 |
$1,014,597 |
D/D |
(5,654) |
2,811 |
|
- |
|
Erck Stanley C |
President and CEO |
|
2021-07-02 |
4 |
AS |
$210.23 |
$11,347,066 |
D/D |
(52,559) |
20,495 |
|
- |
|
Erck Stanley C |
President and CEO |
|
2021-07-02 |
4 |
OE |
$36.60 |
$4,239,511 |
D/D |
52,559 |
73,054 |
|
- |
|
Young James F |
Director |
|
2021-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
75,090 |
|
- |
|
Erck Stanley C |
President and CEO |
|
2021-07-01 |
4 |
AS |
$209.20 |
$11,201,513 |
D/D |
(52,620) |
20,495 |
|
- |
|
Erck Stanley C |
President and CEO |
|
2021-07-01 |
4 |
OE |
$25.60 |
$3,240,965 |
D/D |
52,620 |
73,115 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-06-30 |
4 |
AS |
$208.75 |
$615,848 |
D/D |
(2,896) |
706 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-06-30 |
4 |
OE |
$5.95 |
$42,938 |
D/D |
2,896 |
3,602 |
|
- |
|
Mcmanus Michael A Jr |
Director |
|
2021-06-25 |
4/A |
OE |
$0.00 |
$0 |
D/D |
3,450 |
9,401 |
|
- |
|
King Rachel K. |
Director |
|
2021-06-25 |
4/A |
OE |
$0.00 |
$0 |
D/D |
3,450 |
6,250 |
|
- |
|
Mcmanus Michael A Jr |
Director |
|
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,900 |
12,851 |
|
- |
|
Douglas Richard |
Director |
|
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,450 |
31,950 |
|
- |
|
King Rachel K. |
Director |
|
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,900 |
9,700 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-06-25 |
4 |
D |
$189.79 |
$76,485 |
D/D |
(403) |
706 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
834 |
1,109 |
|
- |
|
Young James F |
Director |
|
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,590 |
65,090 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-06-25 |
4 |
D |
$189.79 |
$76,485 |
D/D |
(403) |
718 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-06-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
834 |
1,121 |
|
- |
|
Evans Gray C |
Director |
|
2021-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,450 |
19,549 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-06-17 |
4 |
AS |
$183.28 |
$441,887 |
D/D |
(2,411) |
2,811 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-06-15 |
4 |
D |
$187.07 |
$421,656 |
D/D |
(2,254) |
5,222 |
|
- |
|
460 Records found
|
|
Page 9 of 19 |
|
|